Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (USA)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Applications
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Actionable Molecular Diagnostic System for Physicians
- Diagnostic Solutions for Lung Cancer
- Liquid Biopsy Solutions for Breast Cancer
- Diagnostic Solutions for Colorectal Cancer
- Radioactive Drugs for Diagnostics
- Radioactive Drugs for Therapeutics
Tumor Specificity Equipment & Supplies In USA
76 equipment items found
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory ...
by:Onegene Biotechnology based inSuwon, SOUTH KOREA
OGB23501 is a first-in-class tri-specific tumor microenvironment (TME) immune activator, which simultaneously targets PD-1, CTLA-4, and VEGF. We aim to develop it as a potential backbone therapy for melanoma, NSCLC, HCC, and renal ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
Off-the-shelf products contain 6-12 shared tumor-specific antigen derived peptides optimized for a population. They are personalized with a candidate companion diagnostic test (CDx). In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high ...
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
MV010/MV004, in cancer immunotherapy • Significant increase of tumor specific cytotoxic T cells infiltrating the tumor microenvironment by combining MV010/MV004 to anti-PD-L1 administration in murine models. • Significantly improved tumor eradication and resistance to subsequent grafting and improved survival in murine models. ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
Azymetric™ is the best-in-class platform for therapeutic antibodies that can simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in unique mechanisms of action not accessible through typical monospecific antibodies. Azymetric™ bispecific antibodies can block multiple signaling pathways, recruit immune cells to tumors, ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
Tumors with specific FGFR aberrations: Solid tumors, Gastric cancer, Myelolymphoid neoplasms PHASE ...
Manufactured by:Context Therapeutics Inc. based inPhiladelphia, PENNSYLVANIA (USA)
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that avoid adverse effects in healthy tissue has been challenging. The tight junction protein Claudin 6 (CLDN6) is a validated therapeutic target for many ...
Manufactured by:Scytek Laboratories Inc based inLogan, UTAH (USA)
Isotype: IgG1, kappa, Species Reactivity: Human, Mouse, and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not react with CLIP (aa 17-39 of ACTH). Anti-ACTH is a useful marker in classification ...
Manufactured by:Scytek Laboratories Inc based inLogan, UTAH (USA)
Species: Mouse, Immunogen: N-terminal fragment of human ACTH conjugated to KLH,Clone: 57,Isotype: IgG1, kappa, Species Reactivity: Human and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not ...
Manufactured by:Scytek Laboratories Inc based inLogan, UTAH (USA)
Species: Mouse,Immunogen: Synthetic peptide corresponding to aa 1-24 of human ACTH, Clone: AH26, Isotype: IgG1, kappa, Species Reactivity: Human, Mouse and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this ...
Manufactured by:NexImmune, Inc. based inGaithersburg, MARYLAND (USA)
NexImmune’s AIM™ platform is the foundation for our unique approach to immunotherapy. Our AIM nanoparticle technology enables the development of immunotherapies that orchestrate specific T cell function and trigger a precise immune response against disease. An AIM™ Adoptive Cellular Therapy (ACT) product is manufactured using an AIM™ nanoparticle cocktail ...
Manufactured by:Histo-Line Laboratories based inPantigliate (MI), ITALY
Species Reactivity: Human, Mouse, and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not react with CLIP (aa 17-39 of ACTH). Anti-ACTH is a useful marker in classification of pituitary ...
Manufactured by:Histo-Line Laboratories based inPantigliate (MI), ITALY
Species Reactivity: Human, Mouse, and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not react with CLIP (aa 17-39 of ACTH). Anti-ACTH is a useful marker in classification of pituitary ...
Manufactured by:Tactiva Therapeutics based inBuffalo, NEW YORK (USA)
Adoptive Cell Transfer (ACT) is a form of immunotherapy that targets tumors specifically and potently by utilizing large numbers of a patient’s own immune cells to target and destroy cancer cells. Typically, starting with a few immune cells derived from the patient’s blood, billions of cancer fighting immune cells are manufactured in a ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
By combining bi-valency with bi-specificity in the tetravalent format, the dual checkpoint molecule utilizes avidity and bi-specificity to improve anti-cancer immune cell function. The specificity enhancement both synergistically enhance and expand the breadth of immune cell activity that is diminished in cancer patients (SEBA). The ...
Manufactured by:Kaio Therapy, LLC based inRaleigh, NORTH CAROLINA (USA)
Kaio Therapy's Immune Activation Heat Therapy is a novel hyperthermia system that delivers precisely controlled heat at the cellular level within a tumor. Because Kaio’s IAHT elegantly induces necrosis while activating a systemic, tumor specific response, it can also serve as a platform for other immunotherapies seeking higher efficacies, ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
The prodrug is a combination of a docetaxel molecule, the potent anticancer drug, and a sugar molecule to enhance solubility covalently linked to a tumor-specific antibody. This molecular combination is not bioactive prior to administration. After infusion and adsorption onto targeted cancer cells facilitated by the cancer-specific monoclonal ...
by:NeoGenomics Laboratories based inFort Myers, FLORIDA (USA)
RaDaR™ is a personalized, multi-tumor liquid biopsy assay that can track a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity. This allows RaDaR™ to detect traces of molecular residual disease (MRD) in a patient following surgery or other treatment for cancer, enabling early ...
Manufactured by:Nuclidium AG based inBasel, SWITZERLAND
Nuclidium AG leverages the unique properties of copper radionuclides to advance precision radiotherapy and diagnostics. Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating diagnostic and therapeutic pairs designed to optimize the safety and efficacy profile in cancer treatment. These radionuclides, including ...
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue that Metaclipse modifies with a ‘protein ...